Hepatology International最新文献

{"title":"sPD-1 as a biomarker in CHB: toward functional and methodological clarity.","authors":"Enhui Lv, Xingxing Yao, Huifang Jiang","doi":"10.1007/s12072-026-11044-0","DOIUrl":"10.1007/s12072-026-11044-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1543-1544"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146258085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarification of guideline-relevant wordings in the APASL 2025 acute variceal bleeding guidelines.","authors":"Perarasu Mohan","doi":"10.1007/s12072-026-11038-y","DOIUrl":"10.1007/s12072-026-11038-y","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1530"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter-Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon.","authors":"Jianxia Dong, Sujun Zheng, Xinyue Chen","doi":"10.1007/s12072-026-11049-9","DOIUrl":"10.1007/s12072-026-11049-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1541-1542"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma\".","authors":"Qiongying Xu, Jiehua Han, Jiali Zhu","doi":"10.1007/s12072-026-11056-w","DOIUrl":"10.1007/s12072-026-11056-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1545-1546"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of testosterone addition to nutrition and exercise on muscle mass in men with cirrhosis: the next trial.","authors":"Vinod Arora, Sushrut Singh, Jaya Benjamin, Varsha Shasthry, Satendra Pal Singh, Guresh Kumar, Shiv Kumar Sarin","doi":"10.1007/s12072-026-11106-3","DOIUrl":"10.1007/s12072-026-11106-3","url":null,"abstract":"<p><strong>Background: </strong>Nutrition supplementation and exercise are the current approaches for managing sarcopenia in patients with cirrhosis. There are limited data on benefits, if any, of supplementing testosterone in cirrhosis with sarcopenia and frailty.</p><p><strong>Methods: </strong>127 patients with cirrhosis and sarcopenia were randomized to receive either nutrition and structured exercise with intramuscular testosterone undecanoate 1000 mg administered at 0, 6, 12, 16, 20, and 24 weeks (NExT group, n = 64) or only structured exercise and nutrition (NEx group, n = 63). Of these, 102 patients completed the 24-week study period as per protocol (NExT, n = 50; NEx, n = 52). The primary endpoint was a ≥ 10% increase in appendicular skeletal muscle index (ASMI) at 24 weeks, assessed by dual-energy X-ray absorptiometry (DEXA).</p><p><strong>Results: </strong>The mean age, MELD (median 14), CTP score (Child A 15.7%, Child B 64.7%, Child C 19.6%) were comparable between groups. On intention-to-treat analysis, a ≥ 10% increase in ASMI was achieved in 41/64 (64.1%) patients in the NExT group compared with 16/63 (25.3%) in the NEx group (p < 0.001). Similar findings were observed in the per-protocol analysis (33/50 [66%] vs. 13/52 [25%]; p < 0.001). A greater proportion of patients in the NExT group demonstrated improvement in hand-grip strength (92% vs. 67.3%, p = 0.002), 6-min walk distance (82% vs. 63.5%, p = 0.04), and reduction in serum ammonia (64% vs. 25%, p = 0.01). Liver frailty index improved significantly in the NExT group compared with the NEx group at 24 weeks (3.98 ± 0.27 to 3.32 ± 0.21 vs. 3.93 ± 0.24 to 3.68 ± 0.22, respectively; p = 0.01). Hospitalization rates were lower in the NExT group (18% vs. 34.6%, p = 0.05), with no apparent major adverse-events with testosterone use.</p><p><strong>Conclusion: </strong>The addition of testosterone therapy to nutrition and structured exercise protocols significantly improves the appendicular muscle mass, reduces frailty and need of rehospitalization in cirrhosis patients with sarcopenia and frailty.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1382-1394"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Shi-Ping Sun, Chen-Xi Wang, Ming-Kai Yuan, Han Min","doi":"10.1007/s12072-026-11132-1","DOIUrl":"10.1007/s12072-026-11132-1","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with unmet clinical treatment needs, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promising therapeutic potential. This study systematically evaluated the efficacy of GLP-1 RAs in treating adult MASH patients via a meta-analysis of randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>Following PRISMA 2020 guidelines, we retrieved RCTs from PubMed, Embase, Cochrane Library and Web of Science. Eligible studies included adult MASH patients treated with GLP-1 RAs vs. placebo/standard care. Two reviewers independently performed literature screening, data extraction and risk-of-bias assessment (RoB 2.0). Meta-analysis was conducted using RevMan 5.4, with subgroup analyses by GLP-1 RA type and intervention duration.</p><p><strong>Results: </strong>A total of 27 RCTs involving 2,687 patients were included. GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (RR = 2.56; 95% CI, [1.90, 3.44]; p < 0.00001; I² = 49%) and liver fibrosis improvement without steatohepatitis worsening (RR = 1.37; 95% CI, [1.06, 1.78]; p = 0.02; I² = 44%). Subgroup analyses showed GLP-1 RAs benefited MASH resolution across subgroups, while fibrosis improvement was only significant for multi-receptor agonists and intervention > 48 weeks. No significant changes in ALT/AST were observed (p > 0.05).</p><p><strong>Conclusions: </strong>GLP-1 receptor agonists are effective for achieving histological remission in MASH. More large-scale, long-term follow-up randomized controlled trials are urgently needed. Trial registration The protocol for our meta-analysis and systematic review was registered and recorded in PROSPERO (registration no. CRD420261287573).</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1372-1381"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging expression profiles and clinical outcomes in HCC target selection.","authors":"Junkun Zhu","doi":"10.1007/s12072-026-11060-0","DOIUrl":"10.1007/s12072-026-11060-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1549-1550"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147304993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological and safety considerations for combination immunotherapy and NA cessation in CHB.","authors":"Jing Han, Di Qiang, Shasha Qiu, Liming Lou","doi":"10.1007/s12072-026-11081-9","DOIUrl":"10.1007/s12072-026-11081-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1557-1558"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond \"left or right\": future implications for study design and endpoints in TIPS portal branch selection.","authors":"Xuyang Liu, Ze Bo, Yanchen Zhong, Mingshan Liu","doi":"10.1007/s12072-026-11113-4","DOIUrl":"10.1007/s12072-026-11113-4","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1559-1560"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child-Turcotte-Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression.","authors":"Dhiraj Agrawal, Dinesh Jothimani, Sherrie Bhoori, Guru N Reddy, Sanjiv Saigal, Mohamed Rela, Vincenzo Mazzaferro","doi":"10.1007/s12072-026-11097-1","DOIUrl":"10.1007/s12072-026-11097-1","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have revolutionized advanced hepatocellular carcinoma (HCC) outcomes in Child-Turcotte-Pugh A (CTP-A) cirrhosis. However, 30-40% of real-world advanced HCC cases involve CTP-B cirrhosis, yet are excluded from pivotal trials, representing a substantial unmet need.</p><p><strong>Methods: </strong>Immunotherapy for CTP-B HCC has not yet been comprehensively reviewed. This narrative review summarizes the latest evidence on ICIs in CTP-B HCC through January 2026, evaluating ICI efficacy, safety, and patient selection algorithms across CTP-B subclasses. We present a balanced perspective on pre-ICI portal hypertension screening/prophylaxis, decompensation triggers/recompensation strategies, immune-mediated hepatitis differentiation, locoregional therapy sequencing, and transplant-bridging risks with ICI in the CTP-B patient population.</p><p><strong>Results: </strong>ICIs demonstrate modest efficacy with tolerable safety in well-selected CTP-B7-B8 HCC patients, but require liver-centric considerations to mitigate the risk of decompensation. We propose liver-centric trial endpoints and a multidisciplinary (oncology-hepatology-transplant) framework to improve outcomes in this hard-to-treat population, and to include CTP-B HCC patients in clinical trials to address evidence gaps.</p><p><strong>Conclusions: </strong>This review provides comprehensive guidance on ICIs for CTP-B HCC, identifying key clinical practices and knowledge gaps to inform real-world use and future research.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1299-1317"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}